

Substitute for form 1449A/PTO MAY 0 1 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/986,234

Filing Date October 22, 2001

First Named Inventor Lazar

Group Art Unit 1645-1644

Examiner Name Not Yet Assigned

Attorney Docket Number 053893-5032-01

RECEIVED MAY 03 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	Kind Code (if known)		
132	5,023,243		Tullis	06-11-1991
	5,498,531		Jarrell	03-12-1996


FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Country Code	Number	Kind Code (if known)		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
132	Berger et al., 1996, Endocrinology 137:4189-4195		
	Burriss et al., 1999, Mol. Endocrinol. 13:410-417		
	Cohen et al., 1996, Adv. Chromatogr. 36:127-162		
	Fujita et al., 1983, Diabetes 32:804-810		
	Fujiwara et al., 1988, Diabetes 37:1549-1558		
	Henry, 1997, Endo. Metab. Clin. North Amer. 26:553-573		
	Hiragun et al., 1988, J. Cell. Physiol. 134:124-130		
	Inzucchi et al., 1998, N. Engl. J. Med. 338:867-869		
	Kawamatsu et al., 1980, Arznein.-Forsch./Drug Res. 30:454-459		
	Kletzien et al., 1992, Mol. Pharmacol. 41:393-398		
	Kumar et al., 1996, Diabetologia 39:701-709		
	Larkins, 1997, TEM 8:187-191		
	Lemberger et al., 1996, Annu. Rev. Cell Dev. Biol. 12:335-363		
	Lukkarinen et al., 1997, Stroke 28:639-645		
	Olefsky, 1985, Am. J. Med. 79:1-7		
	Reaven, 1993, Ann. Rev. Med. 44:121-131		
	Schwartz et al., 1998, N. Engl. J. Med. 338:861-866		
	Spencer and Markham, 1997, Drugs 54:89-101		
	Suter et al., 1992, Diabetes Care 15:193-203		
	Watkins and Whitcomb, 1998, N. Engl. J. Med. 338:916-917		
	Wianny and Zernicka-Goetz, 2000, Nature Cell Biol. 2:70-75		
	Wilson et al., 1996, J. Med. Chem. 39:665-668		

Examiner Signature	<i>[Signature]</i> 2/31/05	Date Considered	
--------------------	----------------------------	-----------------	--

1-PH/1590111.1

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/986,234
		Filing Date	October 22, 2001
		First Named Inventor	Mitchell A. Lazar et al.
		Group Art Unit	1632-1644
		Examiner Name	Anne-Marie Falk, Ph.D.
		Attorney Docket Number	053893-5032-01
Sheet	1	of	1




U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS						
Exr Initials	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ₁
	Country Code	Number	Kind Code (if known)			
<i>[Signature]</i>		WO 98/58061		Schering Corporation	12-23-1998	
		WO 99/11293		Human Genome Sciences, Inc.	03-11-1999	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ₁

Examiner Signature	1-PH/2051909.1 <i>[Signature]</i> 7/31/05	Date Considered	
--------------------	---	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/986,234	
			Filing Date	October 22, 2001	
			First Named Inventor	M. Lazar	
			Group Art Unit	1632	
Examiner Name	A. Falk				
Sheet	1	of	3	Attorney Docket Number	UPN-L2066AUSA


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	2001-0011077	08-02-2001	Albone et al.	
	AB	2002-0111476	08-15-2002	Franz-Bacon et al.	
	AC	2003-0166906	09-04-2003	Moore et al.	
	AD	2004-0018980	01-29-2004	Gurney et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	WO-00/00610	01-06-2000	Lal et al.		
	AM	WO-00/04923	02-03-2000	Albone et al.		
	AN	WO-00/05259	02-03-2000	Albone et al.		
	AO	WO-00/20447	04-13-2000	Shimkets		
	AP	WO-99/31236	06-24-1999	Bougueleret et al.		
	AQ	WO-99/55868	11-04-1999	Gurney et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/986,234	
			Filing Date	October 22, 2001	
			First Named Inventor	M. Lazar	
			Group Art Unit	1632-1641	
Examiner Name	A. Falk				
Sheet	2	of	3	Attorney Docket Number	UPN-L2066AUSA

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
JLH	AR	FORMAN et al., "Unique response pathways are established by allosteric interactions among nuclear hormone receptors", <i>Cell</i> May 19, 1995 81(4):541-550		
	AS	FRIEDMANN, T., "Overcoming the obstacles to gene therapy", <i>Sci. Amer.</i> June 1997 276(6):96-101		
	AT	HOLCOMB et al., "FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family", <i>EMBO J.</i> August 1, 2000 19(15):4046-4055		
	AU	KLIEWER et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma", <i>Proc. Nat. Acad. Sci. USA</i> April 29, 1997 94(9):4318-4323		
	AV	MUKHERJEE et al., "Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists", <i>Nature</i> May 27, 1999 386(6623):407-410		
	AW	ORKIN et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy", December 7, 1995		
	AX	REGINATO et al., "Mechanisms by which Thiazolidinediones Enhance Insulin Action", <i>Trends Endo. Metab.</i> December 1999 10(1):9-13		
	AY	STEPPAN et al., "A family of tissue-specific resistin-like molecules", <i>Proc. Nat. Acad. Sci. USA</i> January 16, 2001 98(2):502-506		
	AZ	STEPPAN et al., "Resistin and obesity-associated insulin resistance", <i>Trends Endo. Metab.</i> January-February 2002 13(1):18-23		
	BR	STEPPAN et al., "The hormone resistin links obesity to diabetes", <i>Nature</i> January 18, 2001 409(6818):307-312		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Use as many sheets as necessary)

Sheet	3	of	3	Attorney Docket Number	UPN-L2066AUSA
-------	---	----	---	------------------------	---------------

6